Noven
products are sold in all
major international markets.
|
Over
the past decade, Noven’s technological
advantages have attracted strategic partners who seek to offer leading-edge
transdermal
therapies, including:
| Novogyne
Pharmaceuticals |
In
the U.S., Noven has licensed its menopausal hormone therapy
patches to Novogyne Pharmaceuticals, a women’s health
products company that is a joint venture between Noven and
Novartis Pharmaceuticals Corporation. Vivelle-Dot®,
Novogyne’s
lead product, is the most dispensed transdermal estrogen
therapy in the U.S.
|
| Novartis
Pharma AG |
In
Europe, Noven has licensed its HT patches to Novartis Pharma
AG, a global leader in transdermal HT. Estradot®,
the international version of Vivelle-Dot®, is currently
available in European markets.
|
| Sanofi-aventis |
Noven
has licensed its HT patches to Sanofi-aventis for marketing
in Japan. |
| Apotex
Corp. |
In
the U.S., Noven (through Hisamitsu) has licensed its Fentanyl
Transdermal System to Apotex Corp., one of the top 10 generic
pharmaceutical companies in the U.S. |
For
additional information, contact Noven
Business Development. |
